上遊生物

2023年7月21日

21 - 7 - 2023 / 06:30 CET(中央東部東京)/ c發行人單獨負責這個聲明的內容。減少每股資產淨值(NAV) 0.6%的季度審查由於不利的貨幣發展盡管抑製了市場環境,有吸引力的出口仍有可能,以幾家投資公司投資組合仍遠平衡和價值創造潛力的完整的季度結果推到紅HBM不利的貨幣發展醫療保健投資關閉2023/2024財年第一季度在2023年6月30日1100萬瑞士法郎的損失。每股資產淨值(NAV)在此期間下降了0.6%,而股價下跌了5.6%。投資貨幣,投資組合記錄一個積極的結果在截至2023年6月30日的三個月。然而,不利的貨幣兌瑞郎發展(美元-2.2%,人民幣和歐元-1.5% -7.3%)資產淨值減少了3.2%的總報告季度導致一個小整體損失。私營企業的投資組合的發展私營企業負擔的季度結果與淨600萬瑞士法郎。這包括消極的貨幣發展1300萬瑞士法郎。以下事件引人注目:上遊生物籌集了2億美元的新資本。HBM醫療投資參與這個融資共有1000萬美元的部分。由於人民幣升值,現有投資的價值增加了1200萬瑞士法郎。 Further value adjustments due to completed or pending financing rounds were made at 1000Farmacie (CHF +2.4 million), Farmalatam (CHF -6.9 million) and Fore Biotherapeutics (CHF -2.4 million). Developments in the portfolio of public companies The value of public companies increased by CHF 9 million net, even though currency developments burdened the quarterly result with CHF 37 million. Cathay Biotech, the largest position, announced a strategic collaboration with China Merchants Group (CMG) which will invest up to RMB 6.6 billion (approx. CHF 800 million) in the company. Furthermore, CMG commits to purchasing large quantities of bio-based polyamides from Cathay and cooperate in the area of research and development. Although Cathay's share price increased slightly in the quarter under review, the negative currency development resulted in an overall net value reduction of just under CHF 17 million. Prometheus Biosciences was acquired by Merck & Co. in April for USD 11 billion. Prometheus develops therapies to treat the inflammatory bowel diseases ulcerative colitis and Crohn's disease. Moreover, Chinook Therapeutics agreed to a USD 3.5 billion takeover bid by Novartis in June. Chinook develops therapies for chronic kidney disease. The two acquisitions resulted in a total profit contribution of CHF 11 million. Developments in the fund portfolio The fund portfolio burdened the result in the quarter under review by about CHF 6 million, CHF 4 million of which was due to currency developments. Asset allocation The portfolio remains well balanced with public companies accounting for 44 percent of consolidated assets (of which 26 percent were formerly private companies), 35 percent private companies, 9 percent funds and 12 percent cash and cash equivalents as well as other assets. Outlook The market environment remains dominated by investor concerns about inflation, rising interest rates and a cooling economy. Currency developments also continued to create headwinds at the beginning of the quarter. For the portfolio companies, however, this challenging financing environment also offers opportunities. As the examples of Upstream Bio, Prometheus Biosciences and Chinook Therapeutics demonstrate, companies with convincing research results benefit from high demand and attractive offers in financing rounds and acquisition bids. With the aforementioned strategic agreement with CMG, Cathay Biotech has laid a solid foundation for further growth. In addition, the loc Overall, with a carefully selected portfolio and a solid balance sheet, HBM Healthcare Investments remains ideally positioned to take advantage of opportunities and benefit from positive market momentum. The Quarterly Report June 2023 is available on the Company’s website www.hbmhealthcare.com/en/investors/financial-reports. Contact For further information, please contact Dr Andreas Wicki on +41 41 710 75 77, or at andreas.wicki@hbmhealthcare.com. End of Inside Information